The Road Ahead: Molecular Profiling, Novel Agents, and Quality-of-Life Considerations скачать в хорошем качестве

The Road Ahead: Molecular Profiling, Novel Agents, and Quality-of-Life Considerations

A regional roundtable discussion, moderated by Shilpa Gupta, MD, Cleveland Clinic, examined current and emerging strategies in mHSPC and CRPC, including biomarkers and imaging in treatment selection, evolving use of doublet and triplet therapy, ARPI choices and toxicity considerations, and more. Dr. Gupta was joined by other practitioners at Cleveland Clinic, including Christopher Wee, MD; Abdo Haddad, MD; Adriana Alvarez, MD; Moshe Ornstein, MD; and Brian Haines, MD. In the final segment, they conclude with reflections on the most exciting upcoming developments in HSPC and CRPC, highlighting targeted therapies, PSMA-directed treatments, and personalized medicine based on molecular profiling. They also discuss potential strategies for de-escalating therapy to preserve quality of life and address cardiovascular and metabolic health concerns in prostate cancer patients.